C4 Therapeutics director granted 62,000 stock options

C4 Therapeutics director Laura Bessen received a new stock option grant covering 62,000 shares of common stock.

Rhea-AI Filing Summary

C4 Therapeutics director Laura Bessen received a new stock option grant covering 62,000 shares of common stock. The option has an exercise price of $4.25 per share and expires on June 23, 2036. This is a compensation-related award, not an open‑market trade.

According to the terms, the option vests and becomes fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, as long as Bessen continues serving on the board through that date. After this grant, she holds 62,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 62,000 shares

Grant/Award 1 txn

Insider Bessen Laura

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	62,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 62,000 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Key Figures

Option grant size: 62,000 options Exercise price: $4.25 per share Expiration date: June 23, 2036 +3 more

6 metrics

Option grant size 62,000 options Stock Option (Right to Buy) covering common stock

Exercise price $4.25 per share Exercise price of the stock option grant

Expiration date June 23, 2036 Option expiration for the 62,000-share grant

Vesting date June 24, 2027 Latest vesting date, or earlier at next annual meeting

Shares underlying option 62,000 shares Underlying C4 Therapeutics common stock

Post-transaction holdings 62,000 derivative securities Total options held directly after grant

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 4.2500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become exercisable financial

"This option shall vest and become exercisable in full upon the earlier"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did C4 Therapeutics (CCCC) director Laura Bessen receive in this Form 4?

Laura Bessen received a stock option grant for 62,000 shares of C4 Therapeutics common stock. The award is a compensation-related option, not a market purchase, and gives her the right to buy shares at a fixed exercise price in the future.

What is the exercise price and term of Laura Bessen’s C4 Therapeutics option grant?

The option has an exercise price of $4.25 per share and expires on June 23, 2036. This long-term term allows significant time for potential exercise if vesting conditions are met and Bessen chooses to convert the option into common shares.

When do Laura Bessen’s C4 Therapeutics options vest according to the Form 4?

The option vests and becomes exercisable in full on the earlier of June 24, 2027, or the next annual meeting of C4 Therapeutics stockholders. Vesting also requires her continued service on the company’s board through the applicable vesting date.

Is Laura Bessen buying or selling C4 Therapeutics stock in this Form 4 filing?

She is not buying or selling shares in the open market. The Form 4 reports a grant of 62,000 stock options as compensation, which is classified as an acquisition of derivative securities rather than a purchase or sale of existing common shares.

How many C4 Therapeutics derivative securities does Laura Bessen hold after this transaction?

Following the reported grant, Bessen holds 62,000 derivative securities related to C4 Therapeutics common stock. These represent options rather than currently owned shares and are exercisable only after the specified vesting conditions are satisfied in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:28 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bessen Laura

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.25	06/24/2026		A		62,000		(1)	06/23/2036	Common Stock	62,000	$0	62,000	D

Explanation of Responses:

1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)